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Abstract
Background: Our aim was to assess internal consistency reliability, construct validity, and test-retest reliability of the
HDQ with adults living with HIV in Canada and Ireland.
Methods: We recruited adults 18 years of age or older living with HIV from hospital clinics and AIDS service
organizations in Canada and Ireland. We administered the HDQ paired with reference measures (World Health
Organization Disability Assessment Schedule, SF-36 Questionnaire, Medical Outcomes Study Social Support Survey), and
a demographic questionnaire. We calculated HDQ disability presence, severity and episodic scores (scored from 0–100).
We calculated Cronbach’s alpha and Intraclass Correlation Coefficients (ICC) (Canada only) for the disability severity and
episodic scores and considered coefficients >0.80 and >0.70 as acceptable, respectively. To assess construct validity, we
tested 40 a priori hypotheses of correlations between scores on the HDQ and reference measures and two known
group hypotheses comparing HDQ presence and severity scores based on age and comorbidity. We considered
acceptance of at least 75 % of hypotheses as demonstrating support for construct validity.
Results: Of the 235 participants (139 Canada; 96 Ireland), the majority were men (74 % Ireland; 82 % Canada) and were
taking antiretroviral therapy (88 % Ireland; 91 % Canada). Compared with Irish participants, Canadian participants were
older (median age: 48 versus 41 years) and reported living with a higher median number of comorbidities (4 versus 1).
Cronbach’s alpha for Irish and Canadian participants were 0.97 (95 % confidence interval (CI): 0.97–0.98) and 0.96
(95 % CI: 0.95–0.98), respectively, for the severity scale and 0.98 (95 % CI: 0.97–0.98) and 0.96 (95 % CI: 0.95–0.98),
respectively, for the episodic scale. Of the 40 construct validity correlation hypotheses, 32 (80 %) and 22 (55 %) were
supported among the Canadian and Irish samples respectively; both (100 %) known group hypotheses were also
supported. ICC values for Canadian participants ranged from 0.80 (95 % CI: 0.71, 0.86) in the cognitive domain to 0.89
(95 % CI: 0.83, 0.92) in the social inclusion domain.
Conclusions: The HDQ demonstrates internal consistency reliability and a variable degree of construct validity when
administered to adults living with HIV in Canada and Ireland. The HDQ demonstrates test-retest reliability when
administered to adults with HIV in Canada. Further validation of the HDQ outside of Canada is needed.
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Background
In developed countries such as Canada and Ireland
where individuals living with HIV have access to treat-
ment, HIV is increasingly experienced as a chronic ill-
ness. At the end of 2011, over 71,000 people were living
with HIV in Canada and 7800 in Ireland [1, 2]. In both
countries, the majority of new infections continue to
include men who have sex with men (46 % Ireland; 47 %
Canada) with 23–25 % of new diagnoses occurring
among women [3]. As people with HIV in these coun-
tries are living longer, they are facing similar issues re-
lated to comorbidity and aging, such as bone and joint
disorders, mental health conditions, cardiovascular dis-
ease, cancer, and neurocognitive decline [4–8]. Forming
international partnerships in countries where individuals
experience similar issues related to HIV and aging is
essential to addressing clinical and research priorities in
this emerging field.
The health-related challenges experienced with these
comorbidities in addition to HIV and aging may be
termed, disability. Disability is defined as a combination
of physical, cognitive, mental and emotional symptoms
and impairments; difficulties carrying out day-to-day ac-
tivities; challenges to social inclusion; and uncertainty
about future health that may be experienced as episodic
in nature, fluctuating on a daily basis and over the
extended course living with HIV [9].
Measuring disability in the context of HIV is important
for determining the prevalence and impact of disability as-
sociated with HIV, comorbidities and aging, and for deter-
mining the effectiveness of interventions to reduce the
presence and severity of disability. Dimensions of disability
may overlap with other health-related concepts such
health-related quality of life (HRQL) measured in the con-
text of HIV. In an earlier content analysis we assessed the
extent to which items in existing HIV-specific HRQL ques-
tionnaires captured the health-related challenges experi-
enced by adults living with HIV according to the Episodic
Disability Framework, a conceptual framework developed
from the perspective of adults living with HIV [9, 10]. Many
of the instruments included in this review were developed
prior to the advent of combination antiretroviral therapy
which dramatically changed the course of HIV infection
from a progressively terminal illness to a chronic illness
characterized by periods of wellness and illness [11]. Other
recent developed HIV-specific HRQL questionnaires more
broadly included items related to social relationships and
employment [12, 13]. However these instruments were not
developed to assess the episodic nature of disability; and
components of HRQL such as personal goals, values and
expectations go beyond the scope of disability. Further-
more, evidence demonstrating weak relationships between
symptoms and function (domains of disability) and overall
health-related quality of life suggest HRQL and disability
while related, are distinct concepts, hence both are import-
ant to consider in the context of HIV [14, 15].
Originally developed in Canada, the HIV Disability
Questionnaire (HDQ), is a self-administered instrument
that describes the presence, severity and episodic nature
of disability experienced by adults living with HIV [16].
Developed from the Episodic Disability Framework, the
HDQ is the first known HIV-specific measure of disabil-
ity developed and assessed for use with people living
with HIV [9, 17]. Distinct features of the HDQ include
its description of the daily episodic nature of disability,
and inclusion of uncertainty as a domain of disability.
The HDQ possesses sensibility, including face and
content validity and ease of use for people living with
HIV in Ontario [18]. However, the reliability and validity
of the HDQ for use with people living with HIV in
Canada and other developed countries is unknown.
Our aim was to assess the internal consistency reli-
ability, construct validity, and test-retest reliability of
the HDQ. We specifically focused on Ireland and
Canada due to a funding opportunity to promote
collaborative research between these two countries.
Results from this study will help to establish the role
of the HDQ as a future measure of disability in coun-
tries such as Canada and Ireland where HIV is con-
sidered a chronic illness and individuals experience
similar issues related to HIV, comorbidity and aging.
Methods
We conducted two cross-sectional studies to assess the
measurement properties of the HDQ in Canada and
Ireland. All aspects of this research were conducted in col-
laboration with a Community Advisory Committee based
in Canada comprised of four members including adults liv-
ing with HIV, representatives from AIDS Service Organiza-
tions and a representative from the Ontario Ministry of
Health and Long-Term Care. This research was approved
by Research Ethics Boards at McMaster University,
Hamilton, Ontario, University of Toronto, St. Michael’s
Hospital, Toronto, Ontario, Canada, and St. James’s
Hospital, Dublin, Ireland.
Participants and recruitment
We included adults 18 years of age or older living with
HIV who self-identified as having experienced an epi-
sode of illness attributed to HIV and who were able to
read and understand English. We recruited participants
in southern Ontario, Canada and Dublin, Ireland from
hospital clinics, HIV community-based service organiza-
tions and a specialty hospital (Casey House).
Data collection
We administered the HDQ with seven additional in-
struments: the World Health Organization Disability
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Assessment Schedule 2.0 (WHODAS-2.0), SF-36 Health
Questionnaire (SF-36), Centers for Epidemiologic Studies
Depression Scale (CES-D), Medical Outcomes Study So-
cial Support Survey (MOS-SSS), HIV Symptom Index,
Brief COPE, and HIV Stigma Scale [19–25]. We also ad-
ministered a demographic questionnaire. We administered
the HIV Disability Questionnaire (HDQ) a second time
one week later to the participants in Ontario to assess
test-retest reliability.
HIV disability questionnaire
The HDQ consists of 69 items that describe the pres-
ence, severity and episodic nature of disability experi-
enced by adults living with HIV. The HDQ is comprised
of six domains: physical, cognitive and, mental and emo-
tional health symptoms and impairments, uncertainty,
difficulty with day-to-day activities and challenges to so-
cial inclusion [26]. An additional item asks participants
to classify living with HIV as a ‘good day’ or ‘bad day’.
Each item consists of a statement about a health-related
challenge and has both a five point ordinal response
scale asking the respondent to rate the challenge on the
day of administration (from 0 to 4) and a nominal re-
sponse scale asking whether the challenge fluctuated
(or changed) over the past week (‘Yes’ or ‘No’). Disabil-
ity presence scores are calculated by summing the num-
ber of health challenges experienced for each HDQ
domain and transforming them to a score out of 100.
Disability severity scores are calculated by summing in-
dividual item scores from each domain and then
linearly transforming them into HDQ domain severity
scores out of 100. Episodic scores are calculated by
summing the number of challenges identified as fluctu-
ating in each domain and then transforming them to a
score out of 100. All HDQ scores range from 0–100.
Higher scores indicate a greater presence, severity, and
episodic nature of disability.
World Health Organization Disability Assessment Schedule
2.0 (WHODAS-2.0)
The WHODAS-2.0 contains 36 items that measures dis-
ability across six domains (cognition, mobility, self-care,
getting along, life activities, and participation). Scores
ranges from 0 to 100, where 0 means no disability and
100 means full disability [19]. The WHO-DAS 2.0 has
been used with people living with HIV [27] and pos-
sesses reliability, validity and responsiveness among
people with chronic disease [28].
Brief COPE
The Brief COPE contains 28 items about coping re-
sponses to stressful events living with a health condi-
tion [21]. Brief COPE scoring is divided into an
Adaptive and Maladaptive Coping Score. The Adaptive
Coping Score is the sum of 16 positive coping items re-
lated to active coping, planning, emotional support, in-
strumental support, positive reframing, acceptance,
religion and humor (ranging from 16–64) with higher
scores indicating better coping skills, and the Maladap-
tive Coping Score is the sum of 12 negative coping
items related to venting, denial, substance use, behav-
ioral disengagement, self-distraction and self-blame
(ranging from 12–48) with higher scores indicating
worse coping skills [21].
HIV stigma scale
The HIV Stigma Scale contains 40 items which ask
about social and emotional aspects of having HIV [20].
The HIV Stigma Scale includes four subscales: personal
stigma, disclosure, negative self-image and public atti-
tudes (scores range from 40–160). Higher scores indicate
higher levels of stigma [20]. The HIV Stigma Scale pos-
sesses construct validity and reliability with people living
with HIV [20].
Medical Outcomes Study (MOS) social support scale
The MOS-Social Support Survey contains 19 items that
ask how often companionship, assistance and other
types of support are available if needed [24]. The MOS-
Social Support Score ranges from 0 to 100, where 0
means no support available when needed, and 100
means support is always available when needed [24].
The MOS-Social Support Scale possesses construct val-
idity and reliability when used with people living with
HIV [24].
HIV symptom index
The HIV Symptom Index is a 20-item questionnaire that
describes the presence and burdensome nature of symp-
toms experienced by adults with HIV. Each item is
scored using a five point ordinal scale ranging from ‘I do
not have this symptom’ to ‘I have this symptom and it
bothers me a lot’. HIV Symptom Index scoring involves
summing the number of symptoms that are present and
the number that are considered bothersome. The HIV
Symptom Index demonstrates good construct validity
with people living with HIV [22].
CES-D
The Centers for Epidemiologic Studies for Depression
Scale (CES-D) is a 20-item instrument that measures de-
pressive symptomatology [23]. The Scale possesses high
internal consistency, adequate test-retest reliability and
concurrent and construct validity in the general popula-
tion [23] and has been used extensively with people liv-
ing with HIV [29–33]. Item scores range from 0–60 and
higher scores indicate more depressive symptoms [23].
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SF-36 questionnaire
The SF-36 questionnaire is a generic health-related qual-
ity of life instrument [25, 34]. The measurement proper-
ties of the SF-36 are well established, demonstrating
high internal consistency reliability, content, construct,
and predictive validity [35, 36]. Domain scores for the
SF-36 include physical function, role limitation physical,
bodily pain, vitality, role limitation emotional, mental
health, social function, and general health perception.
Physical Health Component Summary (PCS) and Mental
Health Component Summary (PCS) scores are calcu-
lated from the domain scores. All domain and summary
scores range on a scale from 0–100 with higher scores
indicating better quality of life.
Analysis
All data were entered into a database and 20 % of cases
were independently manually verified for accuracy. We
computed missing response rates for the disability and
episodic sections of the HDQ and the health status mea-
sures. We removed cases with more than 10 % missing
item responses in the HDQ. For all other cases with
missing responses, we performed mean imputation.
We assessed the distribution of HDQ item responses
and domain scores, and health status summary scores.
We classified floor and ceiling effects as >15 % of re-
sponses being at the bottom or top of the scales, respect-
ively [37]. We assessed differences between Canadian
and Irish participants for HDQ and health status
measures using the Mann-Whitney test for continu-
ous variables and chi-square test for categorical vari-
ables (statistical significance p < 0.05). Statistical
analyses were conducted using SAS and SPSS statis-
tical software [38, 39].
Internal consistency reliability
We calculated Cronbach’s alpha for the HDQ severity and
episodic domain and total scores to assess internal
consistency reliability, the degree to which the items
within the instrument are correlated with each other. We
considered Cronbach’s alpha >0.80 as acceptable [40].
Construct validity
We tested 40 a priori construct validity hypotheses
about predicted relationships using correlations between
HDQ severity scores and three health status measures
(WHO-DAS 2.0; SF36 questionnaire; MOS-Social Sup-
port Scale) and two hypotheses comparing HDQ pres-
ence and severity scores based on age and comorbidity.
Specifically, we assessed 15 convergent hypotheses with
the WHO-DAS 2.0 questionnaire, 18 convergent hy-
potheses with the SF-36 questionnaire, and seven diver-
gent hypotheses with the MOS-Social Support Scale.
We also tested two known group hypotheses (greater
presence and severity of disability with age and number
of comorbidities) (Additional file 1). Correlation coeffi-
cients of | ≥ 0.30|, | ≥ 0.50| and | ≥ 0.70|, were defined as
‘weak’, ‘moderate, ’ and ‘strong, ’ respectively [41]. Each
construct validity hypothesis and its corresponding hypoth-
esized level of correlation are provided in Additional file 1.
Fisher transformation was used to normalize the dis-
tribution and stabilize the variance, and to compute
the confidence intervals [42]. We considered accept-
ance of at least 75 % of hypotheses determined by
the correlation coefficient as demonstrating support
for construct validity (Additional file 1) [43].
Test-retest reliability
We assessed test-retest reliability by calculating an intra-
class coefficient (ICC) with Canadian participants who
completed the HDQ at time 1 and time 2, one week
later. We included participants who did not report a
major change in their health between time points and
who reported no change in the ‘good day/bad day’ classi-
fication item. We considered an ICC > 0.70 as acceptable
for test-retest reliability [40, 44].
Sample size estimation
Sample size estimation was based on the validity analysis
and our desire to detect a weak correlation between the
scores of the criterion reference measures and the HDQ
scores. To detect a Pearson’s correlation coefficient of
r = 0.30 with a power of 0.90, and an alpha of 0.05, we
required at least 113 participants [45] for each study.
To adjust for an estimated 15 % of questionnaires with
missing responses and loss to follow-up at time 2 for
the test-retest reliability analyses, we required at least
130 participants. Using a low correlation coefficient
was a conservative approach to sample size estimation.
Results
We recruited 142 participants in Ontario between
April-July 2012 and 101 participants in Dublin between
June-July 2012, of whom 139 and 100 participants were
eligible and agreed to participate, respectively. Four
people from Dublin completed less than half of the
questionnaires and were removed from the dataset,
resulting in 139 Canadian, and 96 Irish participants in
the study (Table 1). The majority of Irish participants
(89; 93 %) were recruited from St. James’s Hospital
GUIDE Clinic in Dublin, whereas the majority of
Canadian participants (129; 91 %) were recruited
from HIV community based service organizations in
southern Ontario.
Characteristics of participants
Of the 235 participants (139 Canada; 96 Ireland), the
majority were men (74 % Ireland; 82 % Canada) taking
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antiretroviral therapy (88 % Ireland; 91 % Canada) with
an undetectable viral load (85 % Ireland; 89 % Canada)
(Table 1). Compared with Irish participants, Canadian
participants were older (median age: 48 versus
41 years), living longer with their HIV diagnosis (me-
dian year of diagnosis 1999 in Canada; 2003 in
Ireland), reported living with a higher number of co-
morbidities (4 in Canada versus 1 in Ireland), tended
to live alone (66 % in Canada versus 29 % in Ireland),
and were less frequently working for pay (21 % in
Canada versus 54 % in Ireland). Canadian participants
tended to rate their health status as either fair or
good whereas Irish participants tended to rate their
health status as very good or excellent (Table 1).
Health status questionnaires
Compared to Irish participants, Canadians had higher
WHO-DAS 2.0 disability scores, lower mental and phys-
ical health summary scores on the SF-36 questionnaire
(indicating lower quality of life), higher CES-D scores
(indicating higher levels of anxiety and depression),
higher HIV Symptom Index Scores (indicating more






Number (%) Number (%)
Gender 0.149
Men 114 (82 %) 72 (74 %)
Women 24 (17 %) 23 (24 %)
Other 1 (1 %) 2 (2 %)
Age (median; 1st–3rd quartile) 48 years (44–55 years) 41 years (34–48 years) <.001*
50 years or older 58 (41 %) 22 (23 %)
Year of Diagnosis (median: 1st-3rd quartile) 1999 (1990–2004) 2003 (1998–2009) <.001*
Diagnosed with HIV prior to 1996 58 (42 %) 13 (14 %) <.001*
Taking antiretroviral therapy 127 (91 %) 84 (88 %) 0.457
Undetectable Viral Loada 110 (89 %) 41 (85 %) 0.463
Currently working for pay 29 (21 %) 52 (54 %) <.001*
Living alone 91 (66 %) 28 (29 %) <.001*
Have children 36 (26 %) 33 (34 %) <.001*
Live with children 11 (8 %) 24 (25 %)
Self-rated health status <.001*
Poor 12 (9 %) 3 (3 %)
Fair 35 (25 %) 10 (10 %)
Good 56 (40 %) 21 (22 %)
Very good 25 (18 %) 34 (35 %)
Excellent 11 (8 %) 26 (27 %)
Number of concurrent health conditions
(median; 1st–3rd quartile)
4 (2–6) 1 (0–3) <.001*
Common concurrent health conditions
Muscle pain 77 (56 %) 21 (22 %) <.001*
Mental health 65 (47 %) 18 (19 %) <.001*
Joint pain 60 (44 %) 22 (23 %) 0.002*
Addiction 43 (31 %) 9 (9 %) <.001*
Neurocognitive decline 43 (31 %) 11 (12 %) <.001*
Hepatitis C 17 (12 %) 21 (22 %) 0.047*
High blood pressure 33 (24 %) 16 (17 %) 0.207
Not all characteristics add to the total n due to missing responses
*Statistically significant difference (p < 0.05) between groups of participants
aout of 123 and 48 responses from Canadian and Irish participants, respectively
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symptoms), higher maladaptive and adaptive coping
scores on the Brief COPE, and lower scores on the
MOS-Social Support Scale (indicating less social sup-
port) (all p < 0.05). Scores were similar between groups
on the HIV Stigma Scale (Table 2).
HIV disability questionnaire
Canadian and Irish participants took a median of 10 min
(1st-3rd quartile: 8–12 min) and 13 min (1st–3rd quartile:
10–15 min) to complete the HDQ, respectively. Missing
item responses were <3 % across all HDQ disability and
episodic items. We observed a ceiling effect (>15 % of
responses indicating the highest severity of disability) for
eight items with Canadian participants and four items
with Irish participants. Ceiling effects were most com-
mon for items pertaining to uncertainty or worrying
about the future. All 69 HDQ items demonstrated a
floor effect (>15 % of responses indicating no disability)
for Canadian and Irish participants. Of these, 28 and 54
HDQ items had >40 % of responses indicating no dis-
ability for the Canadian and Irish participants, respect-
ively. Floor effects were most common for items that
referred to symptoms and impairments or difficulties
with day-to-day activities.
Median HDQ presence, severity and episodic scores
are displayed in Table 3. Highest median disability
presence scores were in the cognitive (Canada: 100) and
uncertainty domains (Ireland: 71). Highest median
disability severity scores were in the uncertainty domain
for both Canada (score: 39) and Ireland (score: 30). The
median episodic score, representing the number of
challenges that fluctuated in the past week, was highest
in the physical symptoms and impairments domain and
similar between samples (20 Ireland and Canada). Me-
dian HDQ severity and presence scores were signifi-
cantly higher among Canadian participants across all
domain and total scores, except for uncertainty for
which they were similar (Table 3).
Episodic HDQ scores were similar between groups.
The most common episodic health challenges in-
cluded fatigue (52 % Canada; 38 % Ireland), followed
by feeling sad, down or depressed (44 % Canada;
35 % Ireland), aches and pains (37 % Canada and
Ireland), nausea (39 % Canada; 20 % Ireland), short-
ness of breath (36 % Canada; 28 % Ireland), and feel-
ing anxious (35 % Canada; 32 % Ireland). Eighty-one
percent (time 1) and 82 % (time 2) of Canadian par-
ticipants and 88 % of Irish participants completed the




All HDQ severity and episodic domain and total scores
met pre-specified criteria for internal consistency reli-
ability. Cronbach’s alpha for the HDQ severity domain
scores ranged from 0.84 (95 % confidence interval (CI):
0.76, 0.92) in the cognitive domain to 0.93 (95 % CI:
0.91, 0.95) in the mental-emotional domains for the Irish
and Canadian participants respectively (Table 4). Cron-
bach’s alpha for the HDQ episodic scores ranged from
0.81 in the cognitive domain to 0.95 in the uncertainty
domain (Table 4).
Construct validity
Of the 40 construct validity correlation hypotheses,
80 and 55 % were supported by Canadian and Irish
participants respectively and both known groups hy-
potheses (100 %) were confirmed (Table 5). Of the
correlation HDQ hypotheses, 87 and 67 % that re-
ferred to the WHO-DAS scores, 78 and 67 % that re-
ferred to the SF36 scores, and 71 and 0 % that
referred to the MOS-Social Support Scale scores were
supported by Canadian and Irish participants respect-
ively. For details on each of the 42 construct validity
hypotheses and resulting correlation coefficients see
Additional file 1. Bolded correlation coefficients and
95 % confidence intervals indicate a given hypothesis
was confirmed (Additional file 1).













(Range 0–100) 30 (18,44) 12 (5,24) <.001*
SF-36 questionnaire (Range 0–100)
Mental component
summary score
39 (32,49) 47 (38,54) 0.001*
Physical component
summary score
43 (35,50) 53 (43,57) <.001*
CES-D summary score
(Range 0–60) 23 (15,33) 13 (6,21) <.001*
HIV symptom index (Range 0–20)
Total # present 16 (11,19) 11 (5,15) <.001*
Total # bothersome 13 (8,16) 7 (3,11) <.001*
HIV stigma scale (Range 40–160) 103 (84,117) 99 (86,118) 0.756
MOS-social support scale
(Range 1–100) 49 (29,74) 63 (43,89) 0.001*
Brief COPE
Adaptive (Range 16–64) 42 (36,48) 37 (30,45) 0.002*
Maladaptive (Range 12–48) 22 (19,28) 20 (16,24) 0.001*
*Statistically significant difference between groups (p < 0.05)
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Test-retest reliability
Ninety-nine Canadian participants reported having no
major change in their health and reported no change in
the good day/bad day item on the HDQ and were in-
cluded in the test-retest reliability analysis. Results dem-
onstrated that the HDQ domain and total scores were
stable over time with ICC values ranging from 0.80
(95 % CI: 0.71, 0.86) in the cognitive domain to 0.89
(95 % CI: 0.83, 0.92) in the challenges to social inclusion
domain (Table 6).
Discussion
The HDQ demonstrated internal consistency reliability
and construct validity when administered to adults living
with HIV in Canada and Ireland. This is the first known
HIV-specific measure developed to assess the presence,
severity and episodic nature of disability among adults
with HIV developed from a conceptual model of disabil-
ity [9]. This study builds on previous evidence that
established the domain and scoring structure of the
HDQ and confirmed the validity of the six domain
structure with adults living with HIV in Ontario [26, 46].
Internal consistency reliability assessment resulted in
Cronbach’s alpha >0.80 for all severity and episodic do-
main and total scores, suggesting the items in the HDQ
are homogeneous within the six HDQ domains to col-
lectively measure the broader construct of disability at
one point in time. Test-retest reliability results among
the Canadian participants indicated ICC ≥0.80 for all
HDQ domain and total scores suggesting the HDQ is
consistent at measuring disability over time.
Pre-specified construct validity criteria were confirmed
for 80 % (Canada) and 55 % (Ireland) of hypothesized re-
lationships between the HDQ and health reference mea-
sures and both known group hypotheses. Thus, our
results indicate that the HDQ satisfied construct validity
(>75 % of hypotheses) for Canadian, but not for Irish,
participants. Differences in construct validity between
Canada and Ireland may be attributed to the mechanism
in which the HDQ and reference measures were admin-
istered. For example, Canadian participants completed
the measures consecutively in one single sitting in a
quiet location at an HIV service organization, whereas
Irish participants completed the measures intermittently
while seeing various health providers in a busy HIV
Table 3 Median HIV Disability Questionnaire (HDQ)scores (n = 235)
Disability dimension HDQ Presence Score (IQR) HDQ Severity Score (IQR) HDQ Episodic Score (IQR)
Canada Ireland P value Canada Ireland P value Canada Ireland P value
Physical 60 (40–60) 35 (15,60) 0.0001* 25 (11, 38) 13 (5,25) 0.0001* 20 (5,55) 20 (0,40) 0.226
Cognitive 100 (33, 100) 33 (0100) 0.0001* 25 (17, 42) 8 (0,25) 0.0001* 0 (0,67) 0 (0,33) 0.167
Mental-emotional 73 (45, 91) 45 (18,80) 0.0001* 30 (13, 50) 14 (7,30) 0.0001* 9 (0,45) 9 (0,36) 0.615
Uncertainty 79 (57, 93) 71 (50,93) 0.073 39 (23, 61) 30 (18,53) 0.086 0 (0,29) 0 (0,36) 0.936
Difficulties with day-to-day activities 56 (22, 89) 11 (0,22) 0.0001* 17 (6, 31) 3 (0,8) 0.0001* 0 (0,22) 0 (0,0) 0.004*
Challenges to social inclusion 67 (50, 92) 42 (19,58) 0.0001* 31 (17, 50) 17 (7,29) 0.0001* 0 (0,17) 0 (0,8) 0.383
HDQ total 70 (43, 81) 43 (26,59) 0.0001* 29 (16, 42) 17 (8,26) 0.0001* 12 (1,39) 12 (3,28) 0.523
*Statistically significant difference between Canadian and Irish participants (Mann-Whitney Test) (p < 0.05)
Table 4 Internal consistency reliability of the HIV Disability Questionnaire (HDQ)
HDQ score HDQ severity score HDQ episodic score
Cronbach’s alpha (95 % CI) Cronbach’ alpha (95 % CI)
Canada Ireland Canada Ireland
Physical 0.92 (0.90, 0.94) 0.89 (0.86,0.92) 0.92 (0.91 , 0.94) 0.88 (0.84,0.92)
Cognitive 0.87 (0.82, 0.91) 0.84 (0.77,0.90) 0.81 (0.74, 0.88) 0.84 (0.76,0.92)
Mental-emotional 0.93 (0.91, 0.95) 0.91 (0.88,0.94) 0.91 (0.89, 0.94) 0.90 (0.87,0.94)
Uncertainty 0.93 (0.91, 0.94) 0.92 (0.90,0.94) 0.95 (0.94, 0.97) 0.94 (0.92,0.97)
Difficulty with day-to-day activities 0.91 (0.83, 0.93) 0.88 (0.83,0.94) 0.92 (0.89, 0.95) 0.85 (0.77,0.93)
Challenges to social inclusion 0.90 (0.88, 0.93) 0.90 (0.85,0.94) 0.94 (0.92, 0.97 0.90 (0.85,0.94)
HDQ total (all items) 0.97 (0.97, 0.98) 0.96 (0.95,0.98) 0.98 (0.97, 0.98) 0.96 (0.95,0.98)
Interpretation: Cronbach alpha > 0.80 defined as acceptable
CI Confidence Interval
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clinic. This may have introduced inconsistencies in the
way participants responded to items across the question-
naires resulting in lower correlations between measures.
For instance, if a participant attended clinic with a level
of disability, the HDQ scores (administered prior to the
health provider encounter) may be higher or lower
compared with SF36 questionnaire scores (administered
post encounter) depending on whether the disability was
influenced by the event of seeing the health provider.
Differences in construct validity also may be attributed
to differences in culture, and the willingness of
participants to disclose their vulnerability to chronic ill-
ness and the health-related challenges of HIV [47].
Cross-cultural adaptation of the HDQ may be consid-
ered when administering the instrument in other coun-
tries with varying culture or perceptions related to
chronic illness [48, 49]. Finally, lower levels of confirmed
hypotheses were found among the seven a priori hy-
potheses for divergent construct validity with the MOS-
Social Support Scale in both samples (71 % Canada; 0 %
Ireland) suggesting we may have overestimated the ex-
tent to which we hypothesized items in the HDQ would
correlate with items of social support.
Notably Canadian participants were older, living longer
with their HIV diagnosis, reported a greater number of
comorbidities, tended to live alone, and fewer were
working for pay in some capacity (full time, part time, or
under the table). These differences were reflected in the
HDQ and health status measures with Canadian partici-
pants reporting higher disability, lower quality of life,
higher depression, more symptoms, and lower levels of
social support compared with Irish participants. Differ-
ences between the samples were likely attributed to the
different mechanism of recruitment across countries.
The majority of the Irish sample (93 %) was recruited
from a hospital clinic that broadly served adults living
with HIV receiving care in Dublin, whereas the majority
of the Canadian sample was primarily recruited from
HIV community-based organizations (91 %), or a spe-
cialty hospital (7 %) whereby participants likely were ex-
periencing health-related challenges requiring them to
seek out additional social support or health services.
Nevertheless, floor effects (scores closer to the lower
end of the scale) were evident across the HDQ in both
samples and to a greater extent among Irish participants.
This may have decreased the ability for Irish HDQ
scores to correlate with the other measures that pos-
sessed more normalized distributions of scores. Floor
and ceiling effects can pose challenges for responsive-
ness and diminish the ability for an instrument to de-
tect a change if one occurs [50]. Removing items that
demonstrate a large floor or ceiling effect, or adding
items at the lower end of the scale, may be consid-
ered in future HDQ revision to increase the distribu-
tion of scores and enhance the ability to discriminate
between participants.
Higher coping scores among the Canadian partici-
pants suggest that they engaged in both adaptive and
maladaptive coping strategies more frequently com-
pared with Irish participants. The higher frequency of
coping may be attributed to the greater comorbidity
and severity of disability experienced by Canadian
participants which may result in their adopting both
forms of coping (adaptive and/or maladaptive) more
frequently. Alternatively, Irish participants who were
Table 5 Summary of construct validity analysis results








15 13 (87 %) 10 (67 %)WHODAS 2.0 scores will moderately
(≥0.50) to strongly (≥0.70) correlate
with HDQ scores
Convergent construct validity
18 14 (78 %) 12 (67 %)SF-36 scores will weakly (≥0.30)
to strongly (≥0.70) correlate with
HDQ scores
Divergent construct validity
7 (71 %) 0 (0 %)MOS-SS scores will weakly (≥0.30)
to moderately (≥0.50) correlate
with HDQ scores
Total # of correlation hypotheses
tested
40 32 (80 %) 22 (55 %)
Known groups validity
2 2 (100 %)
Older participants with more
comorbidity (Canadian sample)
will have higher total HDQ
presence and severity scores
See Additional file 1 for details of all 42 hypotheses and the
correlation coefficients
Table 6 Internal consistency reliability of the HIV Disability
Questionnaire (HDQ) (n = 99)
HDQ domain Intraclass Correlation
Coefficient (ICC) (95 % CI)
(n = 99)
Physical 0.83 (0.64, 0.91)
Cognitive 0.80 (0.71, 0.86)
Mental-emotional 0.88 (0.80, 0.93)
Uncertainty 0.85 (0.78, 0.90)
Difficulty with day-to-day activities 0.86 (0.80, 0.90)
Challenges to social inclusion 0.89 (0.83, 0.92)
HDQ total 0.90 (0.83, 0.94)
Interpretation: ICC >0.70 considered acceptable
Includes Canadian participants with no major change in health and no change
in good day/bad day item (n = 99)
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living with less comorbidity and disability may not feel
the need to adopt these strategies to the same extent.
Unlike all other HDQ domains whereby Canadian
participants reported more disability, uncertainty was
the highest HDQ domain severity score and it was
similar among both Canadian and Irish participants. The
concept of uncertainty is particularly relevant to aging
with HIV, whereby older adults may worry about their
source of health challenges; health providers’ knowledge
and skills; financial uncertainty; transition to retirement;
appropriate long-term housing and who will care for
them as they age living with HIV [51].
Compared with other HDQ domains, physical symp-
toms and impairments tended to fluctuate more on a
daily basis with median HDQ episodic scores greatest in
the physical symptoms domain (20 challenges fluctuated
within the week among Irish and Canadian samples)
followed by mental emotional symptoms and impair-
ments (nine challenges), demonstrating the potential
episodic nature of disability. Items related to symptoms
and impairments such as fatigue, weakness and
trouble concentrating may fluctuate more readily than
those associated with social inclusion such as the
ability to engage or re-engage in the workforce [52].
Specific symptoms and impairments that fluctuated
the most included fatigue, feeling sad, down or
depressed, nausea, aches and pains, shortness of
breath, and feeling anxious. The episodic scale of the
HDQ represents the daily episodic nature of disability
rather than the larger fluctuations in health that may
occur over a longer period of time. Further work is
needed to assess the properties of the HDQ episodic
scale.
The majority of participants (81–88 %) reported com-
pleting the HDQ on a ‘good day’ living with HIV despite
the presence and severity of disability reported in the
HDQ. This may be a reflection of resiliency, adaptation
and hardiness among adults aging with HIV as a chronic
disease [53, 54]. Nevertheless, it is unclear how partici-
pants defined a ‘good day’ versus a ‘bad day’ living with
HIV. Further work exploring the interpretation of this
item as it relates to the HDQ disability scores is needed.
Implications for practice, research and policy
The HDQ may be used by clinicians and HIV commu-
nity organizations to assess disability experienced by
their clients as a result of HIV and other concurrent
health conditions. This may help to identify areas of
need where programs, services and interventions that
reduce disability experienced by clients with HIV can be
effective. Further, given the findings suggest insufficient
validity in Ireland, further refinement and validity assess-
ment of the HDQ beyond Canada is needed. Future revi-
sion of the HDQ also may include a short-form version
to enhance the feasibility of the HDQ for use in the
clinical setting. Future assessment of interpretability will
be critical to understand the meaning of HDQ scores for
adults living with HIV and clinicians. Additional psycho-
metric assessment of responsiveness will enable re-
searchers to use the HDQ to document changes in
disability over time and determine the effectiveness of
interventions.
Our study has limitations. First, the HDQ was devel-
oped with men living with HIV living in a large metro-
politan city who were taking antiretroviral therapy, living
with concurrent health conditions, and not currently
working. Accordingly, the HDQ demonstrated higher
construct validity among Canadian participants who re-
sembled the sample from which the HDQ was originally
derived, validated and refined. While this study was the
first to assess the validity of the HDQ internationally, the
properties of the HDQ among people living with HIV in
the developing country context are unknown. Second,
because our goal was to assess the measurement proper-
ties of the HDQ rather than to measure disability per se,
the HDQ scores should be considered cautiously since
the interpretability of the HDQ scores are unknown.
Lastly, our analysis focused on assessing the construct
validity, internal consistency reliability and test-retest
reliability of the domains of the disability severity scale of
the HDQ. Test–retest reliability assessment was limited
to Canadian participants; hence further investigation of
this property outside of Canada is needed.
Conclusions
The HDQ demonstrates internal consistency reliability
and a variable degree of construct validity when adminis-
tered to adults living with HIV in Canada and Ireland.
The HDQ demonstrates test-retest reliability when admin-
istered to adults with HIV in Canada. Differences in con-
struct validity between countries may be due to lower
HDQ scores among Irish participants who were younger
and reported less comorbidity, and differences in the
mechanism of questionnaire administration. Further work
to explore HDQ applications outside of Canada is needed.
Additional file
Additional file 1: Details of construct validity analysis. (DOCX 229 kb)
Abbreviations
CES-D: Centers for Epidemiologic Studies Depression Scale (CES-D);
CI: Confidence Interval; HIV: Human Immunodeficiency Virus; HDQ: HIV
Disability Questionnaire; HRQL: Health-related quality of life; MOS-SS: Medical
Outcomes Study Social Support Survey; WHODAS-2.0: World Health
Organization Disability Assessment Schedule 2.0.
Competing interests
The authors declare that they have no competing interests.
O’Brien et al. Health and Quality of Life Outcomes  (2015) 13:124 Page 9 of 11
Authors’ contributions
KKO led the conceptual design of the study, acquisition of funding,
recruitment and data collection, conducted the analysis, and drafted the
manuscript. AMB and PS participated in the conceptual design of the study,
acquisition of funding, analytical interpretations and drafting the manuscript.
CB and SOD participated in recruitment and data collection, analytical
interpretations and drafting the manuscript. NI participated in the data
collection, analytical interpretations and drafting the manuscript. PSt
participated in the analytical interpretations, and drafting the manuscript.
All authors read and approved the final manuscript.
Acknowledgements
We gratefully acknowledge the members of the Community Advisory
Committee including Ken King (Canadian Working Group on HIV and
Rehabilitation), James Murray (Ontario Ministry of Health and Long-Term
Care) and Shane Patey (Toronto People With AIDS Foundation) for their
contributions to this work.
We gratefully acknowledge Community Collaborators in this work including
Casey House, Toronto People With AIDS Foundation, Canadian Working
Group on HIV and Rehabilitation, McMaster Special Immunology Services
(SIS) Clinic, the AIDS Network (Hamilton), AIDS Niagara, AIDS Committee of
Durham Region, AIDS Committee of Toronto, GUIDE Clinic at St. James’s
Hospital, and Open Heart House (Dublin, Ireland).
This research was supported by an operating grant from the Canadian
Institutes of Health Research (CIHR) HIV/AIDS Community Based Research
Program (CBR#104072) and a Dobbin Scholarship from the Ireland Canada
University Foundation (ICUF). Dr. Kelly O’Brien is supported by a CIHR New
Investigator Award. Dr. Ahmed Bayoumi was supported by a Canadian
Institutes of Health Research / Ontario Ministry of Health and Long-Term
Care Applied Chair in Health Services and Policy Research. The views
expressed in this article are those of the authors, and no official endorsement
by supporting agencies is intended or should be inferred.
Author details
1Department of Physical Therapy, University of Toronto, 500 University
Avenue, Room 160, Toronto, ON M5G 1V7, Canada. 2Institute of Health
Policy, Management and Evaluation (IHPME), University of Toronto, 4th Floor,
155 College Street, Toronto, ON M5T 3M6, Canada. 3School of Rehabilitation
Science, McMaster University, 1400 Main Street West, Room 408, Hamilton,
ON L8S 1C7, Canada. 4Department of Genito Urinary Medicine and Infectious
Diseases, Hospital 5, St. James’s Hospital, James’s Street, Dublin 8, Ireland.
5Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
6Centre for Research on Inner City Health, Keenan Research Centre of the Li
Ka Shing Knowledge Institute, St. Michael’s Hospital, 30 Bond Street, Toronto,
ON M5B 1W8, Canada. 7Department of Medicine, University of Toronto,
Toronto, ON, Canada.
Received: 5 September 2014 Accepted: 20 July 2015
References
1. Public Health Agency of Canada: Summary: Estimates of HIV Prevalence
and Incidence in Canada. 2011. Available at: http://webqa.phac-aspc.gc.ca/
aids-sida/publication/survreport/estimat2011-eng.php
2. AVERT. AVERTing HIV and AIDS: European HIV and AIDS Statistics. 2011.
Available at: http://www.avert.org/european-hiv-aids-statistics.htm.
3. Health Protection Surveillance Centre (HPSC). HIV in Ireland, 2013.
Dublin: Health Protection Surveillance Centre; 2014.
4. Goodroad BK. HIV and AIDS in people older than 50. A continuing concern.
J Gerontol Nurs. 2003;29:18–24.
5. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep.
2010;7:69–76.
6. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al.
Premature age-related comorbidities among HIV-infected persons
compared with the general population. Clin Infect Dis. 2011;53:1120–6.
7. Mallon PW. Aging with HIV: osteoporosis and fractures. Curr Opin HIV AIDS.
2014;9:428–35.
8. Kendall CE, Wong J, Taljaard M, Glazier RH, Hogg W, Younger J, et al.
A cross-sectional, population-based study measuring comorbidity among
people living with HIV in Ontario. BMC Public Health. 2014;14:161.
9. O’Brien KK, Bayoumi AM, Strike C, Young NL, Davis AM. Exploring disability
from the perspective of adults living with HIV/AIDS: development of a
conceptual framework. Health Qual Life Outcomes. 2008;6:76.
10. O’Brien KK, Bayoumi AM, Strike C, Young NL, King K, Davis AM. How do
existing HIV-specific instruments measure up? Evaluating the ability of
instruments to describe disability experienced by adults living with HIV.
Health Qual Life Outcomes. 2010;8:88.
11. Palella Jr FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al.
Mortality in the highly active antiretroviral therapy era: changing causes of
death and disease in the HIV outpatient study. J Acquir Immune Defic
Syndr. 2006;43:27–34.
12. Duracinsky M, Lalanne C, Le Coeur S, Herrmann S, Berzins B, Armstrong AR,
et al. Psychometric validation of the PROQOL-HIV questionnaire, a new
health-related quality of life instrument-specific to HIV disease. J Acquir
Immune Defic Syndr. 2012;59:506–15.
13. Duracinsky M, Herrmann S, Berzins B, Armstrong AR, Kohli R, Le Coeur S,
et al. The development of PROQOL-HIV: an international instrument to
assess the health-related quality of life of persons living with HIV/AIDS.
J Acquir Immune Defic Syndr. 2012;59:498–505.
14. Mayo NE, Wood-Dauphinee S, Ahmed S, Gordon C, Higgins J, McEwen S,
et al. Disablement following stroke. Disabil Rehabil. 1999;21:258–68.
15. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of
life. A conceptual model of patient outcomes. JAMA. 1995;273:59–65.
16. O’Brien KK, Bayoumi AM, King K, Alexander R, Solomon P. Community
engagement in health status instrument development: experience with
the HIV disability questionnaire. Prog Community Health Partnersh.
2014;8:549–59.
17. O’Brien KK, Davis AM, Strike C, Young NL, Bayoumi AM. Putting episodic
disability into context: a qualitative study exploring factors that influence
disability experienced by adults living with HIV/AIDS. J Int AIDS Soc.
2009;12:5.
18. O’Brien KK, Bayoumi AM, Bereket T, Swinton M, Alexander R, King K, et al.
Sensibility assessment of the HIV disability questionnaire. Disabil Rehabil.
2013;35(7):566–77.
19. World Health Organization. World Health Organizations Disability
Assessment Schedule II (WHO-DAS-II). Geneva: World Health Organization;
2001.
20. Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV:
Psychometric assessment of the HIV stigma scale. Res Nurs Health.
2001;24:518–29.
21. Carver CS. You want to measure coping but your protocol’s too long:
consider the brief COPE. Int J Behav Med. 1997;4:92–100.
22. Justice AC, Holmes W, Gifford AL, Rabeneck L, Zackin R, Sinclair G, et al.
Development and validation of a self-completed HIV symptom Index.
J Clin Epidemiol. 2001;54:S77–90.
23. Radloff LS. The CES-D scale: a self-report depression scale for research in
the general population. Appl Psychol Meas. 1977;1:385–401.
24. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med.
1991;32:705–14.
25. Ware Jr JE, Gandek B. Overview of the SF-36 health survey and the
International Quality of Life Assessment (IQOLA) project. J Clin Epidemiol.
1998;51:903–12.
26. O’Brien KK, Bayoumi AM, Stratford P, Solomon P. Which dimensions of
disability does the HIV Disability Questionnaire (HDQ) measure? A factor
analysis. Disabil Rehabil. 2014;37:1–9.
27. Kemmler G, Schmied B, Shetty-Lee A, Zangerle R, Hinterhuber H,
Schussler G, et al. Quality of life of HIV-infected patients: psychometric
properties and validation of the German version of the MQOL-HIV.
Qual Life Res. 2003;12:1037–50.
28. Meesters JJ, Verhoef J, Liem IS, Putter H, Vliet Vlieland TP. Validity and
responsiveness of the World Health Organization Disability Assessment
Schedule II to assess disability in rheumatoid arthritis patients.
Rheumatology (Oxford). 2010;49:326–33.
29. Lyon DE, Younger JB. Purpose in life and depressive symptoms in persons
living with HIV disease. J Nurs Scholarsh. 2001;33:129–33.
30. Burack JH, Barrett DC, Stall RD, Chesney MA, Ekstrand ML, Coates TJ.
Depressive symptoms and CD4 lymphocyte decline among HIV-infected
men. JAMA. 1993;270:2568–73.
31. Chishinga N, Kinyanda E, Weiss HA, Patel V, Ayles H, Seedat S. Validation of
brief screening tools for depressive and alcohol use disorders among TB
and HIV patients in primary care in Zambia. BMC Psychiatry. 2011;11:75.
O’Brien et al. Health and Quality of Life Outcomes  (2015) 13:124 Page 10 of 11
32. Lyketsos CG, Hoover DR, Guccione M, Senterfitt W, Dew MA, Wesch J, et al.
Depressive symptoms as predictors of medical outcomes in HIV infection.
Multicenter AIDS Cohort Study. JAMA. 1993;270:2563–7.
33. Cook JA, Grey D, Burke J, Cohen MH, Gurtman AC, Richardson JL, et al.
Depressive symptoms and AIDS-related mortality among a multisite cohort
of HIV-positive women. Am J Public Health. 2004;94:1133–40.
34. Ware Jr JE. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25:3130–9.
35. McHorney CA, Ware Jr JE, Raczek AE. The MOS 36-Item Short-Form Health
Survey (SF-36): II. Psychometric and clinical tests of validity in measuring
physical and mental health constructs. Med Care. 1993;31:247–63.
36. McHorney CA, Ware Jr JE, Lu JF, Sherbourne CD. The MOS 36-item
Short-Form Health Survey (SF-36): III. Tests of data quality, scaling
assumptions, and reliability across diverse patient groups. Med Care.
1994;32:40–66.
37. McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice:
are available health status surveys adequate? Qual Life Res. 1995;4:293–307.
38. Corp IBM. SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp;
2010.
39. SAS Institute Inc.: SAS Computer Software 9.2. 2008.
40. Nunnally JC, Bernstein IH. Psychometric Theory. 3rd ed. New York: McGraw-
Hill; 1978.
41. Landis JR, Koch GG. The measurement of observer agreement for
categorical data. Biometrics. 1977;33:159–74.
42. Shen S, Lu Z: Computation of Correlation Coefficient and Its Confidence
Interval in SAS®. AstraZeneca Pharmaceuticals. Wilmington,
Delaware. Avaiable at: http://www2.sas.com/proceedings/sugi31/170-31.pdf
43. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al.
Quality criteria were proposed for measurement properties of health status
questionnaires. J Clin Epidemiol. 2007;60:34–42.
44. Aaronson N, Alonso J, Burnam A, Lohr KN, Patrick DL, Perrin E, et al.
Assessing health status and quality-of-life instruments: attributes and review
criteria. Qual Life Res. 2002;11:193–205.
45. Browner WS, Newman TB, Cummings SR, Hulley SB. Chapter 6: Estimating
sample size and power: The nitty-gritty. In: Designing Clinical Research.
2nd ed. Editors: Hulley SB, Cummings SR, Browner WS, Grady D, Hearst N,
Newman TB. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
46. O’Brien KK, Solomon P, Bayoumi AM. Measuring disability experienced by
adults living with HIV: assessing construct validity of the HIV Disability
Questionnaire using confirmatory factor analysis. BMJ Open. 2014;4,
e005456.
47. Shaw SJ, Huebner C, Armin J, Orzech K, Vivian J. The role of culture in
health literacy and chronic disease screening and management. J Immigr
Minor Health. 2009;11:460–7.
48. Epstein J, Santo RM, Guillemin F. A review of guidelines for cross-cultural
adaptation of questionnaires could not bring out a consensus. J Clin
Epidemiol. 2015;68:435–41.
49. Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process
of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976).
2000;25:3186–91.
50. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al.
The COSMIN checklist for assessing the methodological quality of studies
on measurement properties of health status measurement instruments: an
international Delphi study. Qual Life Res. 2010;19:539–49.
51. Solomon P, O’Brien K, Wilkins S, Gervais N. Aging with HIV and disability:
the role of uncertainty. AIDS Care. 2014;26:240–5.
52. National AIDS Trust. Fluctuating symptoms of HIV. United Kingdom:
National AIDS Trust; 2011.
53. Farber EW, Schwartz JA, Schaper PE, Moonen DJ, McDaniel JS. Resilience
factors associated with adaptation to HIV disease. Psychosomatics.
2000;41:140–6.
54. Emlet CA, Tozay S, Raveis VH. “I’m not going to die from the AIDS”:
resilience in aging with HIV disease. Gerontologist. 2011;51:101–11.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
O’Brien et al. Health and Quality of Life Outcomes  (2015) 13:124 Page 11 of 11
